ENvue Medical Reports 36% Revenue Decline and Increased Net Loss in Q1 2026

ENvue Medical, Inc. (formerly NanoVibronix, Inc.) reported a significant decline in financial performance for the first quarter of 2026, with revenues totaling approximately $653,000, a decrease of 36% from $1,025,000 in the same period of 2025. This decline was primarily attributed to the removal of the PainShield Ultra product from the market, which had historically contributed to higher revenue margins. The company’s gross profit also fell sharply, resulting in a loss of $55,000 compared to a profit of $369,000 in the prior year, reflecting a gross margin of -11% versus 36% in the previous year.

Operating expenses increased substantially, with total operating expenses rising to $3.66 million from $2.22 million year-over-year. Research and development expenses decreased slightly to $468,000 from $530,000, while selling and marketing expenses surged to $772,000, up 121% due to the full impact of ENvue's operating costs following the merger. General and administrative expenses also rose to $2.42 million from $1.34 million, driven by higher legal and consulting fees, as well as costs associated with former executive management.

The company reported a net loss of $3.82 million for the quarter, a 104% increase from the $1.87 million loss in the same quarter of 2025. This increase in net loss was primarily due to decreased revenues and increased operating expenses. The loss available to common stockholders was approximately $22.62 million, significantly impacted by deemed dividends related to the Series H Preferred Stock, which totaled $16.97 million due to down-round adjustments.

As of March 31, 2026, ENvue Medical had cash and cash equivalents of $2.24 million, down from $4.22 million at the end of 2025. The company reported negative cash flow from operations of $4.31 million for the quarter, raising concerns about its ability to sustain operations without additional financing. The company is actively seeking to raise capital through equity offerings and strategic partnerships to support its operations and product commercialization efforts.

Looking ahead, ENvue Medical anticipates continued challenges in achieving profitability, with ongoing reliance on external financing to cover operational losses. The company is focused on stabilizing its product offerings and expanding its market presence, particularly in the enteral feeding sector through its ENvue subsidiary. However, the ongoing geopolitical tensions and macroeconomic conditions may pose additional risks to its operational and financial stability.